A Dose Optimization/Expansion Study of SAR445877 in Adult Chinese Participants With Advanced Gastric or Gastroesophageal Junction Cancer
← catalyst calendarNCT07692204 · readout in 714 d
Sponsored by Sanofi (industry) · SNY — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
30estimated
Sites
1
Country
China
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-07-01 | actual | When the study began enrolling |
| Primary completion | 2028-08-02 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-08-02 | estimated | The whole study's end, after follow-up |
| First posted | 2026-07-09 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-20 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Gastric Cancer
- Oesophageal Carcinoma
Intervention
- Drug: SAR445877
Primary outcome
what the primary-completion date above is the date OFObjective response rate
measured From baseline to the end of study, up to approximately 2 years
Permalink · SNY's whole pipeline · Catalyst calendar · Every registered study · What changed